KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) EBT (2016 - 2025)

Travere Therapeutics' EBT history spans 15 years, with the latest figure at -$21.1 million for Q4 2025.

  • For Q4 2025, EBT rose 65.09% year-over-year to -$21.1 million; the TTM value through Dec 2025 reached -$49.3 million, up 84.63%, while the annual FY2025 figure was -$49.3 million, 84.63% up from the prior year.
  • EBT reached -$21.1 million in Q4 2025 per TVTX's latest filing, down from $25.7 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $25.7 million in Q3 2025 to a low of -$135.8 million in Q1 2024.
  • Average EBT over 5 years is -$64.7 million, with a median of -$74.8 million recorded in 2022.
  • Peak YoY movement for EBT: plummeted 194.77% in 2021, then surged 146.89% in 2025.
  • A 5-year view of EBT shows it stood at -$88.8 million in 2021, then increased by 3.6% to -$85.6 million in 2022, then fell by 3.45% to -$88.5 million in 2023, then surged by 31.84% to -$60.3 million in 2024, then skyrocketed by 65.09% to -$21.1 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's EBT are -$21.1 million (Q4 2025), $25.7 million (Q3 2025), and -$12.7 million (Q2 2025).